Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page

Our products target infectious diseases that have a significant impact on life expectancy and address acute medical needs including:


 

Monoclonal antibodies (mAb) against infectious disease targets are a growing area of interest as a therapeutic modality due to their strong safety profile in humans, remarkably long plasma half-life and low risk of drug resistance.  Aridis has a suite of human mAbs being developed as anti-infective drugs targeting key human pathogens, including S. aureus (including MRSA & MSSA), P. aeruginosa, A. baumannii bacteria and respiratory syncytial virus.  Complementing these mAbs is a broad spectrum anti-infective candidate based on the unique properties of gallium (PanaecinTM).


Products Overview

Pa- Pseudomonas aeruginosa bacteria, LPS- Lipopolysaccharrides, mAb- monoclonal antibody, HAP- Hospital-Acquired pneumonia, VAP- ventilator- associated pneumonia, Sa- Staphylococcus aureus bacteria, BSI- Blood stream,  infection, CF- Cystic Fibrosis, RSV- Respiratory syncytial virus


AR-301 Anti-S.aureus mAb AR-101 Anti-P.aeruginosa LPS mAb Aerucin Anti-P.aeruginosa mAb Panaecin (Gallium Citrate) AR-201 Anti-RSV mAb AR-401 Anti-A.baumannii mAb PHARMACEUTICALS

Breakthrough Therapies for

Antibiotic Resistant Infections

Aridis